Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.30
+0.18 (3.52%)
At close: May 4, 2026, 4:00 PM EDT
5.29
-0.01 (-0.19%)
Pre-market: May 5, 2026, 7:17 AM EDT
Savara Employees
Savara had 70 employees as of December 31, 2025. The number of employees increased by 11 or 18.64% compared to the previous year.
Employees
70
Change (1Y)
11
Growth (1Y)
18.64%
Revenue / Employee
n/a
Profits / Employee
-$1,697,671
Market Cap
1.34B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| AbCellera Biologics | 562 |
| KalVista Pharmaceuticals | 275 |
| Viridian Therapeutics | 252 |
| MapLight Therapeutics | 133 |
| Olema Pharmaceuticals | 131 |
| DBV Technologies | 117 |
| ArriVent BioPharma | 77 |
SVRA News
- 17 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 19 days ago - Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 20 days ago - Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - Business Wire
- 27 days ago - Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 5 weeks ago - Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 7 weeks ago - Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Business Wire
- 7 weeks ago - Savara Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 2 months ago - Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire